P048 Clinical Efficacy of Osimertinib Mesylate Tablets in Treatment of Advanced NSCLC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.10.070
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Osimertinib as First-Line Therapy in Advanced NSCLC: A Profile of Its Use

Drugs and Therapy Perspectives
Pharmacology
2018English

P3.01-53 Comparison of the Treatment Efficacy of Osimertinib in Young and Elderly Patients With T790m-Positive NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P2.13-24 Prospective Efficacy of Osimertinib in Circulating Tumour DNA (ctDNA) T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Osimertinib Treats CNS Metastases in NSCLC

Cancer Discovery
Oncology
2018English

P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA26.10 CNS Activity of Ramucirumab in Combination With Osimertinib in Patients With Advanced T790m-Positive EGFR-Mutant NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.13-17 a Retrospective Study: Central Nervous System Response to Osimertinib in Patients With Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA02.03 ASTRIS: A Real World Treatment Study of Osimertinib in Patients With EGFR T790m-Positive NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Efficacy and Safety of Iodine-125 Brachytherapy Combined With Chemotherapy in the Treatment of Advanced NSCLC in the Elderly

OncoTargets and Therapy
OncologyPharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy